Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame
- PMID: 11958900
- DOI: 10.1016/s0360-3016(01)02731-6
Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame
Abstract
Purpose: This study was performed to evaluate the clinical outcomes of three-dimensional (3D) conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame.
Materials and methods: Forty patients who were treated between July 1998 and November 2000 and were followed for >10 months were included in this study. Of the 40 patients, 31 had primary lung cancer and 9 had metastatic lung cancer. The primary lung cancer was staged as T1N0M0, T2N0M0, and T3N0M0 in 19, 8, and 4 patients, respectively. The primary sites of metastatic lung cancer were the colon in 4, tongue in 2, and osteosarcoma, lung cancer, and hepatocellular carcinoma in 1 each. 3D treatment planning was performed to maintain the target dose homogeneity within 15% and to decrease the irradiated lung volume from >20 Gy to <25%. All patients were irradiated using a stereotactic body frame and received 4 times 10-12 Gy single high-dose radiation at the isocenter during a period of 5-13 days (median 12).
Results: The initial 3 patients received 40, and the remaining 37 patients received 48 Gy after dose escalation. Of the 33 tumors followed >6 months, 6 tumors (18%) disappeared completely after treatment. Twenty-five tumors (76%) decreased in size by 30% or more after treatment. Therefore, 31 tumors (94%) showed a local response. During the follow-up of 4-37 months (median 19), no pulmonary complications greater than National Cancer Institute-Common Toxicity Criteria Grade 2 were noted. Of the 16 patients with histologically confirmed T1N0M0 primary lung cancer who received 48 Gy, all tumors were locally controlled during the follow-up of 6-36 months (median = 19). In 9 tumors with lung metastases that were irradiated with 48 Gy in total, 2 tumors did not show a local response. Finally, 3 tumors (33%) with lung metastases relapsed locally at 6-12 months (median 7) after treatment during the follow-up of 3-29 months (median 18).
Conclusion: 3D conformal hypofractionated single high-dose radiotherapy of 48 Gy in 4 fractions using a stereotactic body frame was useful for the treatment of lung tumors.
Similar articles
-
Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1427-31. doi: 10.1016/j.ijrobp.2005.05.034. Epub 2005 Sep 19. Int J Radiat Oncol Biol Phys. 2005. PMID: 16169670 Clinical Trial.
-
Stereotactic radiotherapy of targets in the lung and liver.Strahlenther Onkol. 2001 Dec;177(12):645-55. doi: 10.1007/pl00002379. Strahlenther Onkol. 2001. PMID: 11789403
-
Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):126-35. doi: 10.1016/s0360-3016(03)00095-6. Int J Radiat Oncol Biol Phys. 2003. PMID: 12694831 Clinical Trial.
-
Radiotherapy of liver malignancies. From whole liver irradiation to stereotactic hypofractionated radiotherapy.Tumori. 2004 Jan-Feb;90(1):73-9. doi: 10.1177/030089160409000116. Tumori. 2004. PMID: 15143976 Review.
-
[Symposium: an attempt at radiation therapy using advanced techniques. 1. Stereotactic radiation therapy using body immobilization for lung tumor].Nihon Hoshasen Gijutsu Gakkai Zasshi. 2005 Jul 20;61(7):918-20. doi: 10.6009/jjrt.kj00003326889. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2005. PMID: 16049399 Review. Japanese. No abstract available.
Cited by
-
Feasibility study of automated framework for estimating lung tumor locations for target-based patient positioning in stereotactic body radiotherapy.Biomed Res Int. 2015;2015:653974. doi: 10.1155/2015/653974. Epub 2015 Jan 5. Biomed Res Int. 2015. PMID: 25629051 Free PMC article.
-
Radiation-induced rib fracture after stereotactic body radiotherapy with a total dose of 54-56 Gy given in 9-7 fractions for patients with peripheral lung tumor: impact of maximum dose and fraction size.Radiat Oncol. 2015 Apr 22;10:99. doi: 10.1186/s13014-015-0406-8. Radiat Oncol. 2015. PMID: 25897487 Free PMC article.
-
Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung.J Thorac Dis. 2014 Apr;6(4):369-74. doi: 10.3978/j.issn.2072-1439.2013.12.03. J Thorac Dis. 2014. PMID: 24688781 Free PMC article.
-
Design, development of water tank-type lung phantom and dosimetric verification in institutions participating in a phase I study of stereotactic body radiation therapy in patients with T2N0M0 non-small cell lung cancer: Japan Clinical Oncology Group trial (JCOG0702).J Radiat Res. 2014 May;55(3):600-7. doi: 10.1093/jrr/rrt135. Epub 2014 Jan 1. J Radiat Res. 2014. PMID: 24385469 Free PMC article. Clinical Trial.
-
Development and evaluation of a clinical model for lung cancer patients using stereotactic body radiotherapy (SBRT) within a knowledge-based algorithm for treatment planning.J Appl Clin Med Phys. 2016 Nov 8;17(6):263-275. doi: 10.1120/jacmp.v17i6.6429. J Appl Clin Med Phys. 2016. PMID: 27929499 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical